The Wellness Company reports clinical benefits in cancer study

Dr. Peter McCullough and colleagues at The Wellness Company have published a study investigating the use of a compounded combination of Ivermectin (25mg) and Mebendazole (250mg) for cancer treatment.

In the report, 197 cancer patients were prescribed the combination. Of the 122 patients who completed a six-month follow-up, 84.4% reported a clinical benefit, which includes tumor shrinkage, stable disease, or no evidence of disease. Specifically, 48.4% of those patients reported the strongest positive outcomes, such as tumor shrinkage or no current evidence of disease. Most reported side effects were described as mild.

The study suggests a dual-action mechanism where Ivermectin disrupts tumor growth pathways and triggers apoptosis, while Mebendazole aims to starve abnormal cells by blocking glucose absorption.